Department of Neurology and Internal Medicine D, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Mol Med. 2010 Jul-Aug;16(7-8):278-86. doi: 10.2119/molmed.2010.00015. Epub 2010 Apr 14.
To date there is no diagnostic biomarker for mild stroke, although elevation of inflammatory biomarkers has been reported at early stages. Previous studies implicated acetylcholinesterase (AChE) involvement in stroke, and circulating AChE activity reflects inflammatory response, since acetylcholine suppresses inflammation. Therefore, carriers of polymorphisms that modify cholinergic activity should be particularly susceptible to inflammatory damage. Our study sought diagnostic values of AChE and Cholinergic Status (CS, the total capacity for acetylcholine hydrolysis) in suspected stroke patients. For this purpose, serum cholinesterase activities, butyrylcholinesterase-K genotype and inflammatory biomarkers were determined in 264 ischemic stroke patients and matched controls during the acute phase. AChE activities were lower (P<0.001), and butyrylcholinesterase activities were higher in patients than in controls (P=0.004). When normalized to sampling time from stroke occurrence, both cholinergic parameters were correlated with multiple inflammatory biomarkers, including fibrinogen, interleukin-6 and C-reactive protein (r=0.713, r=0.607; r=0.421, r=0.341; r=0.276, r=0.255; respectively; all P values<0.001). Furthermore, very low AChE activities predicted subsequent nonsurvival (P=0.036). Also, carriers of the unstable butyrylcholinesterase-K variant were more abundant among patients than controls, and showed reduced activity (P<0.001). Importantly, a cholinergic score combining the two cholinesterase activities discriminated between 94.3% matched pairs of patients and controls, compared with only 75% for inflammatory measures. Our findings present the power of circulation cholinesterase measurements as useful early diagnostic tools for the occurrence of stroke. Importantly, these were considerably more distinctive than the inflammatory biomarkers, albeit closely associated with them, which may open new venues for stroke diagnosis and treatment.
迄今为止,尚无轻度中风的诊断生物标志物,尽管早期已有炎症生物标志物升高的报道。先前的研究表明乙酰胆碱酯酶(AChE)参与中风,而循环 AChE 活性反映了炎症反应,因为乙酰胆碱抑制炎症。因此,改变胆碱能活性的多态性携带者应该特别容易受到炎症损伤。我们的研究旨在评估疑似中风患者的 AChE 和胆碱能状态(CS,乙酰胆碱水解的总能力)的诊断价值。为此,在急性期测定了 264 例缺血性中风患者和匹配对照者的血清胆碱酯酶活性、丁酰胆碱酯酶-K 基因型和炎症生物标志物。患者的 AChE 活性较低(P<0.001),丁酰胆碱酯酶活性较高(P=0.004)。与从中风发生时开始的采样时间相比,这两种胆碱能参数与多种炎症生物标志物相关,包括纤维蛋白原、白细胞介素-6 和 C 反应蛋白(r=0.713,r=0.607;r=0.421,r=0.341;r=0.276,r=0.255;均 P 值<0.001)。此外,非常低的 AChE 活性预测随后的非生存(P=0.036)。此外,不稳定的丁酰胆碱酯酶-K 变体携带者在患者中比在对照中更为丰富,且活性降低(P<0.001)。重要的是,将两种胆碱酯酶活性相结合的胆碱能评分可区分 94.3%的患者和对照组的配对,而炎症标志物仅可区分 75%。我们的研究结果表明,循环胆碱酯酶测量具有作为中风发生的有用早期诊断工具的潜力。重要的是,尽管与炎症生物标志物密切相关,但这些标志物明显更具特征性,这可能为中风的诊断和治疗开辟新途径。